Home/Pipeline/INI-2004

INI-2004

Allergic Rhinitis

Phase 2Active

Key Facts

Indication

Allergic Rhinitis

Phase

Phase 2

Status

Active

Company

Inimmune

About Inimmune

Inimmune is a private, clinical-stage biotech developing disease-modifying immunotherapies based on innate immune system modulation. Its lead programs are two clinical-stage TLR agonists: INI-2004 for allergic rhinitis (Phase 2) and INI-4001 for oncology (Phase 1). The company also has a robust pre-clinical pipeline focused on novel adjuvants and innate immune agonists/antagonists, supported by strategic academic and industry collaborations. Inimmune is pre-revenue and positioned in the high-potential but competitive immunotherapy and vaccine adjuvant markets.

View full company profile

Therapeutic Areas

Allergy Oncology Infectious Disease Vaccine Adjuvants

Other Allergic Rhinitis Drugs

Drug	Company	Phase	Status
RYALTRIS®	glenmark	Marketed	Commercialized; Direct U.S. Launch
Azelastine Hydrochloride	Coral Drugs	Commercial	Active
Budesolv	Marinomed Biotech	Phase 2	Active
CEN501	NeuCen Biomedical	Preclinical	Active